2024 Updates in Gyn Onc

CE

Precision Therapeutic Strategies in Gynecologic Oncology: Updates & Considerations for Managed Care Professionals

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: May 09, 2024

Expiration: November 30, 2024

Laura R. Bobolts
Laura R. Bobolts, PharmD, BCOP
Kelly Romo
Kelly Romo, PharmD, BCOP

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A patient with stage IV, germline BRCA–mutated, and HRD-positive serous ovarian cancer has achieved CR following first-line platinum-based chemotherapy plus bevacizumab. Based on current guidelines and FDA approvals, which of the following would be a cost-effective management approach based on her HRD and BRCA status? 

2.

All the following tests would help determine this patient’s eligibility for newly approved or available clinical trials evaluating novel antibody–drug conjugate therapy in ovarian cancer EXCEPT which one?

3.

An African American patient with newly diagnosed high-risk, MSI-high endometrial cancer talks to her oncologist about her treatment options. Which of the following statements would be part of the value proposition for recommending platinum-based chemotherapy with immunotherapy to her?